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Epidemiological and experimental studies indicate that nons-
teroidal anti-inflammatory drugs (NSAIDS) confer up to a 50%
risk-reduction against colorectal cancer (Janne and Mayer, 2000).
Nevertheless, there has been a reluctance to utilize this strategy in
clinical practice, largely due to concerns of potential gastroin-
testinal toxicity. To decrease gastrointestinal toxicity, NSAIDS
have been developed with selectivity for cyclooxygenase (COX)
2, the isoform of the prostaglandin-producing enzyme not
expressed in normal gastrointestinal mucosa (Warner et al, 1999),
but upregulated early during colon carcinogenesis. Nabumetone
has a seven-fold higher selectivity for COX 2 than COX 1 (DeWitt
et al, 1993) and clinical studies indicate that it is 10–36 times safer
than conventional NSAIDS (Huang et al, 1999). However, data
regarding nabumetone’s ability to protect against colon cancer is
quite limited. 
In the current study, we evaluated the chemopreventive efficacy
of nabumetone using the MIN mouse, the murine equivalent of
familial adenomatous polyposis (FAP), in which germline muta-
tions in the adenomatous polyposis coli (APC) gene lead to
multiple intestinal adenomas. APC truncations initiate most
colorectal cancers, underscoring the biological relevance of this
model. To investigate potential mechanisms of chemoprevention,
we evaluated nabumetone’s ability to induce apoptosis and down-
regulate Bcl-2 both in the MIN mouse and the human colon cancer
cell line HT-29. 
METHODS 
MIN mice 
Approval was obtained from the Institutional Animal Care
Utilization Committee of the University of Nebraska Medical
Center. Twenty-four male MIN mice, 5–6 weeks old (Jackson
Labs, Bar Harbor, ME) were randomized to either a standard AIN
93a diet alone (Harlan Teklad Labs, Madison, WI) or with
nabumetone supplementation at 300 ppm, 600 ppm, or 900 ppm
(kindly provided by SmithKline Beecham, Collegeville, PA).
After 10 weeks on diet, the animals were sacrificed and intestinal
tumours were scored under magnification by an observer blinded
to treatment group. Intestinal scrapings and sections were taken at
sacrifice. 
Cell culture 
HT-29 cells (American Type Cell Culture, Rockville, MD) were
grown in Dulbeccos Modified Essential Media Cells with 10%
fetal calf serum. Apoptosis was quantitated via flow cytometric
determination of the subdiploid fraction of propridium iodine
treated cells. To confirm apoptosis, we utilized the M30
CytoDEATH antibody (Boeringer Manheim, Indianapolis, IN),
which targets a neo-epitope produced from cleavage of cytokeratin
18 by caspase 3 (Carr, 2000). 
Western blot analysis 
Immunoblot analysis was performed on intestinal homogenates
and HT-29 lysates as previously described (Roy et al, 1995).
Membranes were probed with a polyclonal antibody to Bcl-2
(Oncogene Science, Cambridge, MA) or b-actin (Santa Cruz
Biotechnology, Santa Cruz, CA), the latter serving as a gel loading
control along with examination of India Ink stained membranes. 
Tissue section analysis 
Apoptotic cells were identified using a modified terminal
deoxynucleotidyl-transferased UTP nick end labelling (TUNEL)
assay (Frag El-Klenow kit, Oncogene Science, Cambridge, MA).
Immunohistochemistry was performed with a polyclonal antibody
to Bcl-2 (Santa Cruz Biotechnology, Santa Cruz, CA) or the
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monoclonal M30 antibody. Slides were developed with the
Vectastain A, B, C kit (Vector Laboratories, Burlingame, CA). 
RESULTS 
Nabumetone inhibited MIN mouse tumorigenesis 
There were 31.6 ± 3.4 intestinal tumours in the MIN mice fed
the control, AIN 93a diet alone, 87% of which were in the small
intestine. All tumours sampled for histology were adenomas.
Nabumetone caused a dose-dependent reduction in small intestinal
and colonic tumours (Figure 1). 
Nabumetone induced apoptosis in MIN mice and HT-29
cells 
Based on our tumour data, we focused on the control versus
900 ppm nabumetone group for all subsequent analysis.
Nabumetone approximately doubled the apoptosis rate in the
uninvolved colonic epithelium (Figure 2A). This TUNEL data
was confirmed in representative tissue sections by immunohisto-
chemical detection of the M30 cytoDEATH epitope (data not
shown), which is specific for an earlier stage in apoptosis in the
colon (Carr, 2000). In HT-29 cells, nabumetone caused a dose-
dependent induction of apoptosis (r2 = 0.995) (Figure 2B) by
subdiploid fraction analysis and was also duplicated with the
M30 antibody (Figure 2C). 
Nabumetone downregulates Bcl-2 expression 
Nabumetone decreased expression of Bcl-2 in the uninvolved
and adenomatous MIN mouse mucosa (Figure 3). Immuno-
histochemical analysis suggested that this was predominantly
epithelial (Figure 3C). In HT-29 cells, nabumetone’s Bcl-2
downregulation paralleled the induction of apoptosis (Figure 4). 
DISCUSSION 
Nabumetone supplementation was well-tolerated with no evidence
of toxicity or alteration in body weight. This is consistent with
clinical observations (Huang et al, 1999) and results from animal
studies which indicate that nabumetone is much less toxic than
conventional NSAIDS. 
Nabumetone caused a dramatic, dose-dependent reduction in
MIN mouse tumorigenesis which was comparable to reports with
other NSAIDS in this model. For instance, 200 ppm sulindac
resulted in a 17% tumour reduction (Torrance et al, 2000) whereas
the maximal tolerated dose (320 ppm) suppressed 70% of tumours
(Beazer-Barclay et al, 1996). Furthermore, celecoxib, a selective
COX 2 inhibitor, reduced tumour multiplicity by 50–71% (Jacoby
et al, 2000). Therefore, our demonstration that 900 ppm nabume-
tone inhibited small bowel and colonic tumours by 50% and 65%,
respectively, compares favourably with other NSAIDS. Moreover,
given the lack of toxicity, it is conceivable that higher doses could
be used with potentially greater efficacy. 
The data presented herein is the first to demonstrate nabume-
tone’s efficacy in the protection against intestinal tumorigenesis.
While more selective COX 2 inhibitors are available, the modest
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Figure 1 Effect of nabumetone supplementation on (A) colonic and (B)
small bowel tumour number. Nabumetone caused a dose-dependent
reduction in tumors (* P < 0.05 versus control diet)
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inhibition of COX 1 by nabumetone may have advantages in protec-
tion against both colon cancer (Chaluda et al, 2000) and cardiovas-
cular diseases. With regards to the latter, it has been demonstrated
that highly selective COX 2 inhibition may potentially increase
cardiac risk (Bombardier et al, 2000) presumably by increasing
platelet aggregation via inhibition of anti-aggregatory prostacyclin
(derived from endothelial COX 2) while not targeting the pro-
thrombotic platelet COX 1 produced thromboxane (McAdams et al,
1999). Therefore, nabumetone, with its safety and anti-platelet
activity would have advantages from a public health perspective
over conventional as well as highly COX 2 selective NSAIDS. 
To investigate the potential mechanism(s) involved in chemo-
prevention, we evaluated apoptosis in the uninvolved mucosa. The
inhibition of apoptosis is crucial in allowing the otherwise 
short-lived colonocytes to accumulate the requisite mutations
for neoplastic transformation. The induction of apoptosis by nabume-
tone was comparable to reports with other NSAIDS in this model
(Boolbol et al, 1996). Furthermore, our MIN mouse data is rein-
forced by the demonstration that nabumetone treatment of HT-29
cells resulted in a dose-dependent induction of apoptosis. 
The regulation of intestinal apoptosis is complex and multifacto-
rial. However, recent data underscores the paramount role of the Bcl-
2 family. The relative abundance of anti-and pro-apoptotic members
govern the cellular propensity towards apoptosis (Tsujimoto and
Shimizu, 2000). Nabumetone’s downregulation of the anti-apoptotic
Bcl-2 was more marked in uninvolved mucosa then in adenomas, a
finding consistent with its potential role in the early stages of carcino-
genesis (Baretton et al, 1996). Our immunohistochemical analysis
Figure 2 Nabumetone induced apoptosis in both the MIN mice and the human colon cancer cell line HT-29. (A) Apoptosis in the uninvolved colonic mucosa
was assessed by a modified TUNEL assay in MIN mice on the AIN 93a diet alone compared to those supplemented with 900 ppm nabumetone. Data is
expressed as % apoptotic cells (mean ± S.E.) (* P < 0.01). (B) Nabumetone induction of apoptosis in HT-29 cells was dose-dependent. Subdiploid fraction was
assessed at 7 days of treatment with nabumetone and expressed as % apoptotic cells (mean ± S.E.) (*P < 0.05 versus control). (C) Representative flow
cytometric apoptosis analysis utilizing; (i) Subdiploid fraction; (ii) Fraction of cells displaying the M30 epitope. Grey represents vehicle control while black are
nabumetone-treated cells
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Figure 3 The effect of nabumetone 900 ppm supplementation on Bcl-2 was assessed in uninvolved MIN mouse colonic mucosa as well as tumours.
(A) Representative Western blot of Bcl-2. (B) Densitometric analysis of Bcl-2 expression, normalized to AIN 93a diet alone. Data expressed as mean ± S.E.
(* P < 0.05 versus control). (C) Representative immunohistochemistry: (i) Uninvolved colon mucosa from animals on a control diet; (ii) Uninvolved colon mucosa
from animals treated with NAB 900 ppm
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Figure 4 Effect of nabumetone on Bcl-2 expression and apoptosis in HT-29
cells. Cells were treated with 100 mM NAB for the indicated time and
expression assessed by immunoblot analysis. (A) Representative Western
blot of Bcl-2. (B) Densitometric analysis of Bcl-2 expression normalized to
the appropriate vehicle control. (C) Corresponding time-dependent apoptosis
rate (by subdiploid fraction) in the HT-29 cells treated with 100 mM NAB.
These were adjusted for the low level of apoptosis (< 2%) in the vehicle
treated cells. Data expressed as mean ± S.E. (* P < 0.05 versus control)
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qualitatively supports the Western blot analysis (Figure 2).
Furthermore, we demonstrate that nabumetone downregulation of
Bcl-2 in HT-29 cells mirrored induction of apoptosis. Our data is in
agreement with the demonstration that sulindac reduced Bcl-2
expression in both the uninvolved rectal mucosa of patients with FAP
(Winde et al, 1997) and in MIN mouse adenomas (McEntee et al,
1999). The mechanism by which NSAIDS downregulate Bcl-2 is
unclear, with one report implicating prostaglandin E2, (Sheng et al,
1998) although several lines of evidence suggesting that
prostaglandin inhibition may not be essential for either NSAID-
induced apoptosis or chemoprevention (Williams et al, 1997). While
Bcl-2 is clearly of importance in governing colonocyte apoptosis
(Hague et al, 1998), recent studies have also implicated pro-apoptotic
members of the family. For instance, Bak expression correlates with
apoptosis rates in the normal human colon (Liu et al, 1999).
However, in HCT-116, a microsatellite unstable colon cancer cell
line, NSAIDS altered the apoptotic threshold by downregulating
the anti-apoptotic Bcl-XL without changing expression of the pro-
apoptotic Bax (Zhang et al, 2000). This is clearly analogous to our
data with nabumetone in a microsatellite stable cell line. 
In summary, we demonstrate that nabumetone is a safe and
effective as a colon cancer chemopreventive agent, potentially
through induction of apoptosis. While the mechanisms are still not
completely elucidated, our data suggests that Bcl-2 downregula-
tion may be important in this process. 
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